9 Deer Park Drive
United States - Map
Insmed Incorporated, a biopharmaceutical company, focuses on developing and commercializing inhaled therapies for patients with serious lung diseases. Its lead product candidate is ARIKAYCE, an inhaled antibiotic treatment that delivers a proven and potent anti-infective directly to the site of serious lung infections. The companys ARIKAYCE is in Phase II clinical trial for patients with lung infections caused by non-tuberculous mycobacteria (NTM) in the United States and Canada; and completed a Phase III clinical trial in Europe and Canada for cystic fibrosis (CF) patients who have lung infections caused by Pseudomonas aeruginosa. Insmed Incorporated was founded in 1999 and is headquartered in Monmouth Junction, New Jersey.
|Insmed Incorporated’s ISS Governance QuickScore as of Mar 1, 2014 is 9. The pillar scores are Audit: 5; Board: 6; Shareholder Rights: 9; Compensation: 9.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. William H. Lewis ,
Chief Exec. Officer, Pres and Director
|Mr. Andrew T. Drechsler ,
Chief Financial Officer and Principal Accounting Officer
|Dr. Renu Gupta M.D.,
Chief Medical Officer and Exec. VP of Devel.
|Mr. Walter Perkins Ph.D.,
Chief Technology Officer
|Ms. Christine A. Pellizzari ,
Gen. Counsel and Corp. Sec.
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|